Skip to main content
Premium Trial:

Request an Annual Quote

Bruker BioSciences Nets $16.9M in Public Stock Offering

This article has been updated from a previous version, which reported the value of the total public offering, rather than the value of Bruker BioSciences' net proceeds.
 
NEW YORK (GenomeWeb News) — Bruker BioSciences today gained $16.9 million in proceeds from a public offering of its common stock.
 
The company said it sold 2.53 million of its shares at $7.10 per share. An additional 9.4 million shares were sold by four stockholders. Bruker did not realize any of the net proceeds from the sale of stock by these shareholders.
 
Bruker plans to use the proceeds for corporate purposes, including repaying debt and for potential acquisitions.
 
Bruker said 1.6 million shares of this offering were sold after the underwriters exercised an over-allotment option.
 
Bear, Stearns & Co. and UBS Investment Bank are serving as joint bookrunning managers for the offering.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.